|
Mechanismneuraminidase inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date01 Jun 1999 |
/ Not yet recruitingPhase 3 An open label non randomized access study of Trametinib for patients with advanced unresectable (stage IIIc) or distant metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma
比较度他雄胺与坦索罗辛联合用药与坦索罗辛单独用药治疗良性前列腺增生的有效性与安全性研究
[Translation] Comparison of the efficacy and safety of dutasteride combined with tamsulosin and tamsulosin alone in the treatment of benign prostatic hyperplasia
研究度他雄胺与坦索罗辛联合用药在改善50岁以上、有中到重度症状伴前列腺体积增大(≥30ml)和PSA升高(≥1.5ng/ml)的良性前列腺增生患者的症状和生活质量方面是否比坦索罗辛单独用药更有效。
[Translation] To investigate whether the combination of dutasteride and tamsulosin is more effective than tamsulosin alone in improving symptoms and quality of life in men aged 50 years or older with moderate to severe symptoms of BPH with enlarged prostate volume (≥30 ml) and elevated PSA (≥1.5 ng/ml).
/ Active, not recruitingNot Applicable 在中国健康男性志愿者中评价度他雄胺和坦索罗辛药代动力学及药物-药物相互作用的开放、单顺序、三周期研究
[Translation] An open-label, single-sequence, three-period study to evaluate the pharmacokinetics and drug-drug interactions of dutasteride and tamsulosin in healthy Chinese male volunteers
评价度他雄胺和坦索罗辛单独给药和联合给药的药代动力学、安全性及耐受性。
[Translation] To evaluate the pharmacokinetics, safety, and tolerability of dutasteride and tamsulosin, administered alone or in combination.
100 Clinical Results associated with Laboratoire GlaxoSmithKline SAS
0 Patents (Medical) associated with Laboratoire GlaxoSmithKline SAS
100 Deals associated with Laboratoire GlaxoSmithKline SAS
100 Translational Medicine associated with Laboratoire GlaxoSmithKline SAS